Stockreport

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis [Yaho...

UCB SA UNSP/ADR  (UCBJY) 
NASDAQ:AMEX Investor Relations: ucb.com/investors
PDF ankylosing spondylitis (AS) since the recent approvals of BIMZELX ® (bimekizumab-bkzx) in these indications in the U.S. New two-year data demonstrated sustained improv [Read more]